UPDATE: RBC Capital Upgrades Seagen (SGEN) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Seagen (SGEN) PT Lowered to $194 at Guggenheim
August 15, 2022 7:53 AM EDTGuggenheim analyst Michael Schmidt lowered the price target on Seagen (NASDAQ: SGEN) to $194.00 (from $204.00) while maintaining a Buy rating.... More
Seagen loses arbitration against Daiichi Sankyo over drug technology
August 12, 2022 1:39 PM EDT(Reuters) -U.S. drugmaker Seagen Inc said on Friday an arbitrator had ruled in favor of Japan's Daiichi Sankyo over an agreement between the two companies for using its drug technology.
The companies have been locked in a legal battle over patents on Daiichi and AstraZeneca Plc's breast-cancer... More
Seagen (SGEN) Issues Statement on Outcome of Daiichi Sankyo Arbitration, Says "Disappointed"
August 12, 2022 1:14 PM EDT(Updated - August 12, 2022 1:15 PM EDT)
Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (Daiichi Sankyo) relating to the parties 2008 collaboration agreement for the use of Seagens antibody-drug conjugate (ADC) technology. The... More
